NeuroPace (NPCE) EPS (Diluted) Growth (1y) (2021 - 2026)
NeuroPace (NPCE) EPS (Diluted) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | -47.60% |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | 44.49% |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | 18.72% |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | 15.24% |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | -25.88% |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | 44.97% |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | 15.81% |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 71.72% |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 13.96% |
| 10 | NeuroPace | 469.11 Mn | 417.41 Mn | 18.91 Mn | 27.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212.94% |
| Dec 31, 2025 | 69.17% |
| Sep 30, 2025 | 22.13% |
| Jun 30, 2025 | -151.46% |
| Mar 31, 2025 | 34.70% |
| Dec 31, 2024 | -175.98% |
| Sep 30, 2024 | 31.81% |
| Jun 30, 2024 | 26.78% |
| Mar 31, 2024 | 16.28% |
| Dec 31, 2023 | 79.20% |
| Sep 30, 2023 | 40.02% |
| Jun 30, 2023 | 29.44% |
| Mar 31, 2023 | 19.21% |
| Dec 31, 2022 | 30.83% |
| Sep 30, 2022 | -43.52% |
| Jun 30, 2022 | -41.58% |
| Mar 31, 2022 | 97.77% |
| Dec 31, 2021 | 99.72% |
| Sep 30, 2021 | 98.32% |
| Jun 30, 2021 | 98.99% |